ADMA Biologics Inc (ADMA) Q3 2026 Earnings Call Highlights: Asceniv Surge Drives Margin ...

Negative Points

• Bivigam revenue declined to $15.4 million from $19.4 million in the prior quarter and $23.8 million a year ago, due to persistent standard IG pricing and competitive pressures.

• The company continues to face aggressive competitor rebating and discounting in the standard IG market, which it chooses not to match, impacting Bivigam's reported revenue.

• Days sales outstanding (DSOs) increased to 110 days, above the target range of 90 to 105 days, driven by the timing of distributor orders.

• Secondary immunodeficiency patient population growth has been slower than anticipated, representing an untapped but challenging opportunity.

• R&D expense is expected to step up significantly in Q4 2026 to approximately $10 million as SG001 development advances, which may pressure near-term profitability.

• The company did not provide specific timelines for SG001 IND submission or clinical trial initiation, leaving uncertainty around the pipeline's progress.

Q & A Highlights

Q: What were the main drivers behind the Asceniv revenue beat in Q3 2026, and how do they contrast with the weakness seen a few quarters ago? A: CEO Adam Grossman attributed the beat to the culmination of commercial efforts and medical education activities, including real-world evidence publications, enhanced medical education presence, and sales force expansion. He noted increases in prescribers and new patient starts, emphasizing Asceniv remains early in its penetration curve and continues to demonstrate strong outcomes for refractory patients failing standard IG products.

Q: How has month-on-month Asceniv utilization trended relative to the previously stated 2% to 4% growth expectation, and how many patients are currently on therapy? A: CEO Adam Grossman stated Asceniv end-user pull-through demand has been growing month-to-month within previously stated ranges, with year-over-year growth of about 31% and full-year growth expected around 25%. He noted the company has penetrated above the previously stated 4% of the 25,000-patient target market and now has more prescribers than ever before, driven by new patient starts and new prescribers.

Q: What is the outlook for the U.S. immunoglobulin market and Bivigam's positioning amid competitive pressures? A: CEO Adam Grossman noted the global IG market remains undersupplied, but the U.S. market is more competitive, particularly in the outpatient alternate site infusion landscape where new entrants are deep discounting. He sees the U.S. market growing at low to mid-single-digits and expressed optimism that short-dated product pressures are alleviating, positioning Bivigam for potential reversion into 2027, supported by new scientific differentiation data on its safety profile.

Q: What is the status and timeline for SG001, including IND filing and clinical study initiation? A: CEO Adam Grossman expressed strong satisfaction with constructive FDA feedback on the pre-IND package regarding clinical trial design, manufacturing, and testing. While not providing specific guidance, he indicated the company will work expeditiously toward an IND filing, anticipating it sometime next year, and noted the planned trial has potential to be an abbreviated registrational Phase 3 study. CFO Terry Kohler added Q4 R&D spend will step up significantly to approximately $10 million.

Q: How has the day sales outstanding trajectory progressed, and what is the expected impact from the McKesson deal? A: CFO Terry Kohler explained DSOs increased above the 90 to 105 day target range primarily due to timing of orders from authorized distributors, though all receivables continue to be collected with no bad debt history. He noted the strategy to grow volumes with distributors like McKesson that have better payment terms may take longer than previously expected, with no big DSO impact anticipated in the remainder of 2026, but the company will continue working to push DSOs back into target range.

Q: To what extent is McKesson contributing to Asceniv numbers, and is there uptake from the oncology channel for secondary immunodeficiency? A: CEO Adam Grossman stated primary immune deficiency continues to lead growth, while the secondary immune deficiency opportunity remains but has been slower than hoped. He noted the company continues working through those channels and expects opportunity for Asceniv to penetrate that market going forward, with growth drivers spanning the entire immunocompromised patient landscape but primarily in the PI population.

Q: Have there been any changes in the payer environment for Asceniv amid standard IG pricing pressure? A: CEO Adam Grossman confirmed no changes in reimbursement during Q3, with broad commercial payer coverage, good negotiations, and consistent prior authorization processes. He emphasized Asceniv continues to be largely insulated from standard IG oversupply issues, with the company doing a good job carving out appropriate use case patients and seeing durable, recurring patient demand month-over-month.

Q: How long are patients staying on Asceniv therapy, and how does that inform the durability of the business? A: CEO Adam Grossman stated the average Asceniv patient stays on therapy for a year or longer, creating a compounding effect of utilization. He emphasized the business being built represents a durable base that will grow in subsequent months, supported by real-world outcomes data showing reductions in infections, hospitalizations, and overall healthcare utilizationbenefits never before seen with another IG product.

Q: Will the company be in a position to provide 2027 guidance early next year given current stabilization trends? A: While the transcript does not include a direct response to this question from management, CEO Adam Grossman's commentary throughout the call emphasized confidence in Asceniv's durable growth trajectory, Bivigam's potential stabilization and reversion into 2027, and the company's reiterated full-year 2026 revenue guidance of at least $530 million with increased minimum adjusted EBITDA and adjusted net income expectations.

Q: What are the key financial highlights from Q3 2026, including revenue, margins, and earnings growth? A: CFO Terry Kohler reported total revenue of $141.1 million, up 5% year-over-year and 13% sequentially, with Asceniv revenue of $124.7 million growing 31% year-over-year and 21% sequentially. Gross margin reached 71%, expanding approximately 1,450 basis points year-over-year, driven by favorable Asceniv mix and yield-enhanced manufacturing. Adjusted EBITDA was $77.3 million, up 32% year-over-year, GAAP net income reached $49.9 million, up 37% year-over-year, and adjusted basic EPS was $0.23, up 44% year-over-year.

Q: What is the capital allocation strategy, including share repurchases and cash position? A: CFO Terry Kohler reported cash and cash equivalents of approximately $124.6 million as of September 30, with net leverage under half a turn. Year-to-date through September 2026, the company repurchased 16.5 million shares for $181.4 million, representing a 6.3% reduction in shares outstanding versus year-end 2025, toward the previously stated target of $200 million or more in total share repurchases during 2026. Cash from operations was $105 million year-to-date, an increase of over 600% versus the first nine months of 2025.

Q: What is the updated full-year 2026 guidance?

For the complete transcript of the earnings call, please refer to the full earnings call transcript .